Aromatase inhibitors in breast cancer.
Smith
Ian E
IE
Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom. ian.smith@rmh.nthames.nhs.uk
Dowsett
Mitch
M
D000735:Androstenedione / Q000737:chemistry; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001141:Aromatase / Q000494:pharmacology; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000517:prevention & control / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D017697:Premenopause
D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D000735:Androstenedione; D001141:Aromatase